US-India council to lead biopharmaceutical executive mission to India

14 September 2010

The Washington DC-based US-India Business Council (USIBC) says that it will embark on a Life Sciences Executive Mission to coincide with the Biotechnology Industry Organization's first annual international partnering conference in Hyderabad, India, from September 21-22. The mission will be led by US biotech giant Amgen's Romi Singh, executive director of global regulatory affairs and safety at the firm.

According to the recently released "Vision 2020" report produced by ABLE and PricewaterhouseCoopers at the request of India's Department of Industrial Policy and Promotion, the global biopharmaceutical market could be worth $319 billion by 2020. According to the report, India should aim to capture 10% of this market.

The USIBC delegation, consisting of the world's leading biopharmaceutical players, will be meeting with Indian government officials and industry leaders to discuss the policies and innovation ecosystem necessary to ensure that India meets or exceeds that target.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >